Finally, our study assessed whether the effects of SCD1 and FADS2 perturbation observed in vitro in EBV-immortalized LCLs held true in tumor-derived models of EBV+ lymphomas, thereby pointing to potential therapeutic applications. This evidence concerns the gene SCD and lymphoma.